



Aptiom in Kuwait

The Kuwait MoH named-patient coordination pathway — indicative 2026

NEUROLOGY · FOCAL EPILEPSY

The clinical situation

Aptiom (eslicarbazepine acetate) is an FDA-approved anti-seizure medicine for partial-onset seizures as monotherapy or adjunctive therapy in adults and paediatric patients aged 4 years and older, manufactured by Sunovion (Sumitomo Pharma). As a third-generation member of the carbamazepine/oxcarbazepine family, Aptiom offers once-daily dosing and a somewhat cleaner tolerability profile — typically considered when carbamazepine or oxcarbazepine have failed or produced intolerable side effects. Dosing starts at 400 mg daily and titrates over 1–2 weeks to a maintenance target of 800–1,200 mg daily (paediatric weight-based). Class cautions include hyponatraemia monitoring, renal-impairment dose adjustment, and HLA-B*1502 screening in high-prevalence populations.

The pathway, 5 steps

- 1 Consultation with your epileptologist.** Focal epilepsy diagnosis per ILAE, prior ASM history (often including carbamazepine or oxcarbazepine trials), and the Aptiom rationale.
- 2 Kuwait MoH named-patient application.** Physician files with the MoH Drug and Food Control Administration including clinical letter, patient identifier, and product details.
- 3 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner.
- 4 Shipment.** Aptiom ships at controlled room temperature; no cold-chain is required.
- 5 Arrival & titration start.** Your epileptologist initiates and supervises the titration schedule.

Indicative economics

Reference US cash-pay range: USD 600–900 per month at maintenance dose (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete Kuwait MoH application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and Kuwait MoH review, keyed to the focal-epilepsy rationale. **Logistics.** Room-temperature shipment coordination. **Concierge case lead.** Named point of contact for ongoing refills. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating epileptologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Aptiom × Kuwait first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/aptiom-kuwait.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team